171 related articles for article (PubMed ID: 30529689)
1. Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Kim IY; Shim MJ; Lee DM; Lee AR; Kim MA; Yoon MJ; Kwon MR; Lee HI; Seo MJ; Choi YW; Choi KS
Biochem Pharmacol; 2019 Apr; 162():41-54. PubMed ID: 30529689
[TBL] [Abstract][Full Text] [Related]
2. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.
Lee DM; Kim IY; Seo MJ; Kwon MR; Choi KS
Exp Mol Med; 2017 Aug; 49(8):e365. PubMed ID: 28798402
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.
Li X; Li M; Ruan H; Qiu W; Xu X; Zhang L; Yu J
Oncotarget; 2017 Feb; 8(6):9280-9292. PubMed ID: 28030835
[TBL] [Abstract][Full Text] [Related]
5. ISRIB plus bortezomib triggers paraptosis in breast cancer cells via enhanced translation and subsequent proteotoxic stress.
Lee DM; Seo MJ; Lee HJ; Jin HJ; Choi KS
Biochem Biophys Res Commun; 2022 Mar; 596():56-62. PubMed ID: 35114585
[TBL] [Abstract][Full Text] [Related]
6. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
7. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
Prevedel NE; Mee MW; Wood GA; Coomber BL
Vet Comp Oncol; 2024 Mar; 22(1):96-105. PubMed ID: 38237918
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
11. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
12. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
13. SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib.
Ohoka N; Nagai K; Shibata N; Hattori T; Nara H; Cho N; Naito M
Cancer Sci; 2017 May; 108(5):1032-1041. PubMed ID: 28192613
[TBL] [Abstract][Full Text] [Related]
14. PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca
Lee HJ; Lee DM; Seo MJ; Kang HC; Kwon SK; Choi KS
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269789
[TBL] [Abstract][Full Text] [Related]
15. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
16. GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma.
Luo J; Xia Y; Luo J; Li J; Zhang C; Zhang H; Ma T; Yang L; Kong L
Cancer Lett; 2017 Dec; 410():112-123. PubMed ID: 28947141
[TBL] [Abstract][Full Text] [Related]
17. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160
[TBL] [Abstract][Full Text] [Related]
19. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis.
Park SS; Lee DM; Lim JH; Lee D; Park SJ; Kim HM; Sohn S; Yoon G; Eom YW; Jeong SY; Choi EK; Choi KS
Carcinogenesis; 2018 Mar; 39(3):458-470. PubMed ID: 29329420
[TBL] [Abstract][Full Text] [Related]
20. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
